Roche’s Fenebrutinib Cuts Annualized MS Relapse Rate 55% Versus Comparator in Phase III Trials

• Roche's Genentech announced Phase III results showing investigational fenebrutinib reduced chronic brain inflammation versus active comparators in multiple sclerosis.
• The findings will be presented at MSToronto2026, October 21-23 in Toronto.
• Fenebrutinib also reduced relapses, slowed brain tissue loss and lowered disability progression in pooled relapsing multiple sclerosis trials.
• Ocrevus maintained relapse control in children with multiple sclerosis; Enspryng showed improved recovery following attacks in MOGAD.
• A U.S. decision on Enspryng for MOGAD is expected in January 2027, potentially making it the first FDA-approved treatment for the disease.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Roche Holding AG published the original content used to generate this news brief via Business Wire (Ref. ID: 202610210800BIZWIRE_USPR_____20261021_BW411479) on October 21, 2026, and is solely responsible for the information contained therein.